4 mg CLS-TA + Sham + IVT aflibercept
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Macular Edema
Conditions
Macular Edema, Retinal Vein Occlusion
Trial Timeline
Jan 1, 2015 → Mar 1, 2016
NCT ID
NCT02303184About 4 mg CLS-TA + Sham + IVT aflibercept
4 mg CLS-TA + Sham + IVT aflibercept is a phase 2 stage product being developed by Clearside Biomedical for Macular Edema. The current trial status is completed. This product is registered under clinical trial identifier NCT02303184. Target conditions include Macular Edema, Retinal Vein Occlusion.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02303184 | Phase 2 | Completed |
Competing Products
20 competing products in Macular Edema
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IVT aflibercept + Sham SC + SC CLS-TA | Clearside Biomedical | Phase 2 | 44 |
| CLS-AX + Anti-VEGF | Clearside Biomedical | Phase 1/2 | 33 |
| suprachoroidal CLS-TA + suprachoroidal sham + Lucentis or Avastin | Clearside Biomedical | Phase 3 | 69 |
| CLS-AX + Aflibercept | Clearside Biomedical | Phase 2 | 44 |
| Eylea + ALT-L9 | Alteogen | Phase 1 | 33 |
| KVD001 Injection | KalVista Pharmaceuticals | Phase 2 | 47 |
| KVD001 Injection | KalVista Pharmaceuticals | Phase 1 | 28 |
| FYB203 2 mg (0.05 mL of 40 mg/mL) | Formycon AG | Approved | 77 |
| FYB201 0.5 mg (0.05 mL of 10 mg/mL) | Formycon AG | Approved | 77 |
| UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL) | Unity Biotechnology | Phase 2 | 44 |
| UBX1325 | Unity Biotechnology | Phase 2 | 44 |
| Aflibercept + foselutoclax | Unity Biotechnology | Phase 2 | 44 |
| UBX1325 | Unity Biotechnology | Phase 1 | 25 |
| CT-P42 + Eylea | Celltrion | Phase 3 | 77 |
| Faricimab + Aflibercept | Chugai Pharmaceutical | Phase 3 | 77 |
| Faricimab + Aflibercept | Chugai Pharmaceutical | Phase 3 | 77 |
| DS-7080a + Ranibizumab | Daiichi Sankyo | Phase 1 | 33 |
| Fovista® + bevacizumab + ranibizumab + aflibercept | Astellas Pharma | Phase 2 | 52 |
| MA09-hRPE | Astellas Pharma | Pre-clinical | 23 |
| volociximab | Astellas Pharma | Phase 1 | 33 |